INTRODUCTION
Subacute thyroiditis (SAT) is a virus-induced disease. It affects 12 in 100,000 people, women are 3 to 5 times more susceptible than men [1]. Though most cases of the disease are self-limited, there is a risk of recurrence. In addition, 22.8% [2] to 26.8% [3] of patients develop permanent hypothyroidism. The predictive factors for development of permanent hypothyroidism are high cumulative doses of glucocorticoids, female gender [3], antibody positive and post-partum SAT [4], treatment with ibuprofen alone [2].

There is a rising evidence of post-COVID-19 subacute thyroiditis, making its treatment a relevant topic for discussion [5-11].

The treatment of SAT according to American Thyroid Association Guidelines includes symptomatic usage of non-steroidal anti-inflammatory agents (NSAIDs) to reduce pain which is followed by administration of prednisone in case NSAIDs don’t reduce pain effectively. Beta-blockers are used to relieve the symptoms of thyrotoxicosis [12].

The current treatment regimens result in a high rate of recurrence (19.8% [2]) and persistent hypothyroidism. This implies a need for optimization of current practice and a search for new treatment options.

THE AIM
The aim of the study was to compare effectiveness of intrathyroid steroid injection (ISI) versus oral steroid administration.

MATERIALS AND METHODS
Total of 149 patients with diagnosed SAT that underwent treatment at Sumy Laser Clinic in years 2019 – 2021 32 patients were included in the study. Diagnosis criteria were pain in thyroid gland, preceding viral respiratory infection, ESR > 30 mm/hour, C-reactive protein > 10 mg/l, diffuse heterogeneity and focal hypoechoic regions with a decreased color flow Doppler on sonography. Inclusion criteria were age between 30 and 60 years, no sufficient result from NSAIDs treatment for at least 10 days, ESR > 30 mm/hour, normal TSH and free T4 levels. Exclusion criteria were any acute or chronic condition that would limit the ability of the patient to participate in the study, refusal to give informed consent, pregnancy, diabetes mellitus, lactation, simultaneous intake of phenobarbital, rifampicin, phenytoin, ephedrine, diuretics, cardiac glycosides, amphotericin B, anticoagulants, antiplatelet agents, and somatotropin.

Written consent has been obtained from each patient or subject after full explanation of the purpose and nature of all procedures used

Patients were randomly divided into two groups 16 patients each by the day of birth 1-12 and 13-31 respectively.

The 1st group received a course of prednisone 20 mg per day for 4 weeks.

The second group received two ISIs with an interval of 4 weeks: at baseline and at 2 weeks control admission.

Steroid used for the ISI was Depos (PIC Farmak, Kyiv, Ukraine). 1 ml of the substance contains 2 mg of betamethasone (6.43 mg of betamethasone dipropionate micronized and 2.63 mg of betamethasone sodium phosphate). It is a combination of fast-soluble
betamethasone sodium phosphate and slow-solvable micronized betamethasone dipropionate, which grants both a rapid (1 hour) and a postponed effect (>10 days).

The procedure is held as follows: 1 ml of the drug is pre-mixed with 2% 1 ml lidocaine in a syringe with 12 mm needle; the front area of the neck is treated with chlorhexidine; the mixture of steroid and lidocaine is injected evenly into the thyroid (both lobes and the isthmus) supported by ultrasound guidance to avoid blood vessels. Distance between injections is approximately 10 mm. After the procedure, the skin is again treated with chlorhexidine. The entire procedure lasts for 15 minutes, including ultrasound identification of the areas of interest and performing the injection.

The results of the therapy were ultrasound-controlled by a highly experienced sinologist with image review at the baseline admission, 2, 4, 8, and 16 weeks later.

Images of the thyroid ultrasound were saved and processed with ImageJ program. Hypoechogenity area was measured in pixels with ImageJ tool for area measurement on the images of transverse and longitudinal thyroid ultrasound. The probe for the images was placed on the patient’s thyroid so that the maximum area of the hypoechogenity could be visualized. Salivary gland

| Table I. Mean hypoechogenity and ESR changes in patients of both groups. |
|---------------------------|-------------------|-----------------|-----------------|-----------------|-----------------|
| TW0, M (SD)   | TW2, M (SD)   | TW4, M (SD)   | TW8, M (SD)   | TW16, M (SD)   |
| Mean hypoechogenity area, px |
| 1st group, n=16 |
| 9991,9 (4014,7) | 5622,2 (2896) | 911,8 (1324,7) | 220,1 (880,3) | 0,00 (0) |
| 2nd group, n=16 |
| 10661 (4222,6) | 9253,5 (4222,9) | 3034,3 (3351,1) | 629,5 (1528,4) | 5712,3 (2705,7) |
| Mean ESR, mm/hour |
| 1st group, n=16 |
| 41,88 (10,09) | 14,06 (9,02) | 5,81 (3,95) | 5,88 (6,05) | 4,50 (2,31) |
| 2nd group, n=16 |
| 42,06 (7,38) | 20,63 (10,81) | 10,44 (5,21) | 11,69 (14,05) | 10,94 (13,49) |
| Mean CRP, mg/l |
| 1st group, n=16 |
| 27,92 (6,73) | 5,63 (3,61) | 2,33 (1,58) | 2,35 (2,42) | 1,8 (0,92) |
| 2nd group, n=16 |
| 28,04 (4,92) | 8,25 (4,33) | 4,18 (2,09) | 4,68 (5,62) | 4,38 (5,40) |

**Fig. 1.**

- a. 45-year-old woman from the 1st group with subacute thyroiditis. Longitudinal sonogram of heterogeneous right thyroid lobe: a1) hypoechoic areas (arrowheads) at baseline; a2) 2 weeks dynamics of hypoechoic areas.
- b. 50-year-old woman from the 1st group with subacute thyroiditis and a thyroid cyst: b1) hypoechoic areas (arrow heads) at baseline; b2) 8 weeks dynamics.
PAINFUL SUBACUTE THYROIDITIS TREATMENT APPROACH

echogenicity was used as a gauge for normal thyroid echogenicity evaluation.

Laboratory analysis included ESR evaluation via Westergren method and CRP quantitative analysis on Behring Nephelometer.

Statistical analysis was held with Windows Excel data package, using Student’s t test. The data were approximately normally distributed and thus did not violate the assumptions of the t test.

The study was approved by the Bioethics Commission of the Medical Institute of Sumy State University.

RESULTS AND DISCUSSION

SONOGRAPHY FINDINGS

At the baseline sonography (treatment week (TW) 0), all the patients had typical findings for the SAT: diffuse heterogeneity and focal hypoechoic regions that showed a decreased color flow Doppler. Surrounding tissue had a decreased color flow Doppler in 14 patients, 15 had an enhanced flow and 3 had normal one. Mean area of hypoechoic regions in the 1st group was 9992 px (95% CI = 7985 to 11999 px) and 10661 px (95% CI 8550 to 12772 px) in the 2nd group. Mean ESR of patients was 41,9 mm/hour (95% CI = 36,8 to 46,9 mm/hour) in the 1st group and 42,1 mm/hour (95% CI = 38,4 to 45,8 mm/hour) in the 2nd. Mean CRP of patients was 27,9 mg/L (95% CI = 24,6 to 31,3 mg/L) in the 1st group and 28 mg/L (95% CI = 25,6 to 30,5 mg/L) in the 2nd (Table I).

At the second admission (TW 2), 16 patients of the 1st group and 7 patients of the 2nd group showed a decrease in sizes of hypoechoic region by more than 10% (Fig 1).

Patients of the 1st group showed a significantly faster result: mean decrease in hypoechoigeny area compared to TW 0 was 44,42% (95% CI = 37,59 to 51,25%) in the 1st group vs 16,35% (95% CI = 7,33 to 25,37%) in the 2nd group (p < 0,001). Mean ESR of patients in the 1st group was significantly lower than of those in the 2nd group: 14,1 mm/hour (95% CI = 9,6 to 18,6 mm/hour) vs 20,6 mm/hour (95% CI = 15,2 to 26 mm/hour); p = 0,024. Mean CRP of patients in the 1st group was as well significantly lower than those in the 2nd group: 5,6 mg/L (95% CI = 3,8 to 7,4 mg/L) vs 8,3 mg/L (95% CI = 6,1 to 10,4 mg/L); p = 0,035.

At the third admission (TW 4) among patients of the 1st group, 10 had no signs of a lesion and 6 still had them, though hypoechoigeny decreased in sizes. Mean decrease in hypoechoigeny area was 93,29% in the 1st group (95% CI = 88,38 to 98,19%) vs 75,98% (95% CI = 61,84 to 88,11%) in the 2nd, p < 0,001. Mean ESR of patients in the 1st group was still significantly lower than of those in the 2nd group: 5,8 mm/hour (95% CI = 3,8 to 7,8 mm/hour) vs 10,4 mm/hour (95% CI = 7,8 to 13 mm/hour); p = 0,022. At this point patients of the 1st group underwent the second injection, while the patients of the 2nd group had their steroids gradually discontinued by 2,5 mg/week.

At TW 8 control admission, the patients of the 2nd group showed the following results: 13 were clinically stable and 3 had signs relapse: thyroid ultrasound showed focal echogenicity with decreased blood flow on Doppler. They also had elevated ESR (35,41 and 42 mm/hour). 1 patient in the 1st group still showed a slightly painful thyroid with some residual focal hypoechoigeny on ultrasound (area = 3521 px) and elevated ESR (28 mm/hour).

He was administered ibuprofen 400 mg twice daily for 5 days and pain didn’t relapse after discontinuation. All the other patients of both groups showed no signs of SAT on ultrasound (Figure 1), normal ESR and CRP. ESR was normal in all patients but one with a relapse in the 1st group (28 mm/hour) and 3 patients in the 2nd group (35, 41 and 42 mm/hour).

At TW 16 patients of the second group with a relapse still showed high ESR levels: 37, 37 and 40 mm/hour and sonographic signs of SAT. All other patients showed a stable result with no signs of inflammation.

SIDE EFFECTS

None of the patients of the 1st group developed steroid-related side effects compared to the 2nd group: 6 patients had an increase in weight > 5%, 5 developed glucose intolerance, 4 had hypertension and 2 women had irregular menses.

ISI has been a debated and poorly studied treatment option recently. First ISI was held in 1974 [13]. In 1986, a patient was treated for severe recurrent Hashimoto thyroiditis with multiple intrathyroid injections of triamcinolone. This study was remarkable for the histological finding that showed an improvement in histological picture even on the day following injection, which showed a reformation of follicular structure and a reduction in epithelial cells swelling [14]. ISI was proved to inhibit Th2 cells in Graves’ disease [15], which may also play a role in SAT pathogenesis [16]. Five cases of painful Hashimoto thyroiditis were successfully treated with injection of triamcinolone [17, 18]. In 2009 study, which included 191 patients with Graves’ disease, ISI proved to successfully prevent a relapse [19]. A comprehensive meta-analysis is being held with no results published yet [20].

The current research proves ISI to be safe and effective in treatment of SAT. Though most cases of SAT are well controlled with NSAIDs, there are still many patients requiring steroids. Not only steroids can cause side effects in the doses given to reduce inflammation, but they also don’t guarantee fast stable effect without recurrence.

CONCLUSIONS

ISI showed a rapid local effect without systemic or local side effects. It showed definitely faster result compared to systemic steroids: at TW 2 mean decrease in hypoechoigeny area of 44,42% (95% CI = 37,59 to 51,25%) in the 1st group vs 16,35% (95% CI = 7,33 to 25,37%) in the 2nd group (p < 0,001). Mean ESR of patients in the 1st group was significantly lower than of those in the 2nd group: 14,1 mm/hour (95% CI = 9,6 to 18,6 mm/hour) vs 20,6 mm/hour (95% CI = 15,2 to 26 mm/hour); p = 0,024. Mean CRP of patients in the 1st group was still significantly lower than of those in the 2nd group: 5,6 mg/L (95% CI = 3,8 to 7,4 mg/L) vs 8,3 mg/L (95% CI = 6,1 to 10,4 mg/L); p = 0,035.

At TW 8 control admission, the patients of the 2nd group showed the following results: 13 were clinically stable and 3 had signs relapse: thyroid ultrasound showed focal echogenicity with decreased blood flow on Doppler. They also had elevated ESR (35,41 and 42 mm/hour). 1 patient in the 1st group still showed a slightly painful thyroid with some residual focal hypoechoigeny on ultrasound (area = 3521 px) and elevated ESR (28 mm/hour).

Still there is a need for evaluation of drug absorption ratio, as thyroid is a greatly vascularized tissue. However, even if there is a systemic effect of steroid, ISI still requires much lower dosage to influence thyroid gland and there is no evidence of steroid-related side effects. All possible local side effects can be easily avoided due to US-navigation.
It is also suitable for uncompliant patients. The result can be monitored by ultrasound alone and most of the patients require only one injection to achieve complete curation.

REFERENCES

ORCID and contributionhip:
Inna O. Forkert: 0000-0003-2777-0307 B,C,D
Oksana K. Melekhovets: 0000-0001-9031-7009 A,E,F
Yurii V. Melekhovets: 0000-0002-3219-9021 B
Evgen L. Kovalenko: 0000-0003-0750-9945 F
Dmitro O. Kalynychenko: 0000-0001-9031-7009

Conflict of interest:
The Authors declare no conflict of interest.

CORRESPONDING AUTHOR
Inna O. Forkert
Sumy State University
10 Lebedinska Str, app. 35, 40021 Sumy, Ukraine
tel: +380955364942
e-mail: i.forkert@med.sumdu.edu.ua

Received: 22.03.2021
Accepted: 30.07.2021

A – Work concept and design, B – Data collection and analysis, C – Responsibility for statistical analysis, D – Writing the article, E – Critical review, F – Final approval of the article